| Citation: |
SONG Yufei, WANG Chenglong, ZHANG Huiyuan, ZHANG Yan, ZHAO Wei, ZHAO Qichao, ZHANG Yanlei, LI Nan. Correlation Between PD-L1 Expression and 18F-FDG Uptake in Lung Adenocarcinoma[J]. Cancer Research on Prevention and Treatment, 2019, 46(11): 994-997. DOI: 10.3971/j.issn.1000-8578.2019.19.0500
|
To evaluate the relation between the expression of programmed cell death protein receptor-1 (PD-L1) and 18F-deoxyglucose (18F-FDG) uptake in lung adenocarcinoma.
We retrospectively analyzed the clinical data of 102 patients with pathologically-confirmed lung adenocarcinoma who underwent 18F-FDG PET/CT examinations before treatment and immunohistochemical examination after treatment to detect the expression of PD-L1. The relation between the maximum standard uptake of 18F-FDG(SUVmax) and the expression of PD-L1 was analyzed.
PD-L1 positive were detected in 50 patients (49%), the SUVmax was significantly higher in PD-L1 positive patients than that in the negative patients (6.59±5.03 vs. 2.89±4.65, P=0.0001). For the prediction of PD-L1 expression by SUVmax, the area under the ROC curve was 0.801, P=0.0001; when the cut off value was 1.70, the maximum value of Jordan index was 0.522.
18F-FDG uptake is associated with PD-L1 expression in primary lung adenocarcinoma, and the patients with high SUVmax are more likely to harbor PD-L1 expression.
| [1] |
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30. doi: 10.3322/caac.21387
|
| [2] |
Wu K, House L, Liu W, et al. Personalized targeted therapy for lung cancer[J]. Int J Mol Sci, 2012, 13(9): 11471-11496. doi: 10.3390/ijms130911471
|
| [3] |
Boyerinas B, Jochems C, Fantini M, et al. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells[J]. Cancer Immunol Res, 2015, 3(10): 1148-1157. doi: 10.1158/2326-6066.CIR-15-0059
|
| [4] |
Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030): 1837-1846. doi: 10.1016/S0140-6736(16)00587-0
|
| [5] |
Remon J, Chaput N, Planchard D. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer[J]. Curr Opin Oncol, 2016, 28(2): 122-129. doi: 10.1097/CCO.0000000000000263
|
| [6] |
Sidaway P. Skin cancer: Avelumab effective against Merkel-cell carcinoma[J]. Nat Rev Clin Oncol, 2016, 13(11): 652. http://cn.bing.com/academic/profile?id=d1bb5bbebb949b8c40bef393249ed079&encoded=0&v=paper_preview&mkt=zh-cn
|
| [7] |
Prasad S, Hu S, Sheng WS, et al. The PD-1: PD-L1 pathway promotes development of brain-resident memory T cells following acute viral encephalitis[J]. J Neuroinflammation, 2017, 14(1): 82. doi: 10.1186/s12974-017-0860-3
|
| [8] |
Hanna N, Johnson D, Temin S, et al. Systemic Therapy for Stage Ⅳ Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update[J]. J Clin Oncol, 2017, 35(30): 3484-3515. doi: 10.1200/JCO.2017.74.6065
|
| [9] |
Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study[J]. Lancet Oncol, 2016, 17(11): 1497-1508. doi: 10.1016/S1470-2045(16)30498-3
|
| [10] |
Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study[J]. Lancet Oncol, 2017, 18(1): 31-41. doi: 10.1016/S1470-2045(16)30624-6
|
| [11] |
Cyriac G, Gandhi L. Emerging biomarkers for immune checkpoint inhibition in lung cancer[J]. Semin Cancer Biol, 2018, 52(Pt2): 269-277. http://cn.bing.com/academic/profile?id=07b345d9c90d61ff0d65e0865fd69e05&encoded=0&v=paper_preview&mkt=zh-cn
|
| [12] |
Takada K, Toyokawa G, Tagawa T, et al. Association Between PD-L1 Expression and Metabolic Activity on (18)F-FDG PET/CT in Patients with Small-sized Lung Cancer[J]. Anticancer Res, 2017, 37(12): 7073-7082. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=748ba03a01b62c87432d7f637dd5a72f
|
| [13] |
Zhang M, Wang D, Sun Q, et al. Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma[J]. Oncotarget, 2017, 8(31): 51630-51640. http://europepmc.org/abstract/MED/28624803
|
| [14] |
付立武.非小细胞肺癌组织中PD-L1蛋白表达与18F FDG-PET/CT显像特征的关系[J].临床肺科杂志, 2019, 24(1): 107-110. doi: 10.3969/j.issn.1009-6663.2019.01.027
Fu LW. Relationship between the expression of PD-L1 proteinand the features of 18F and FDG PET/CT in non-small cell lung cancer[J]. Lin Chuang Fei Ke Za Zhi, 2019, 24(1): 107-110. doi: 10.3969/j.issn.1009-6663.2019.01.027
|
| [15] |
Lopci E, Toschi L, Grizzi F, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery[J]. Eur J Nucl Med Mol Imaging, 2016, 43(11): 1954-1961. doi: 10.1007/s00259-016-3425-2
|
| [16] |
马薇, 罗殿中, 陈源, 等. PD-L1和PD-1在非小细胞肺癌中的表达及其临床意义[J].实用医学杂志, 2011, 27(9): 1551-1554. doi: 10.3969/j.issn.1006-5725.2011.09.013
Ma W, Luo DZ, Chen Y, et al. Expression and clinical significance of PD-L1 and PD-1 in non-small cell lung cancer[J]. Shi Yong Yi Xue Za Zhi, 2011, 27(9): 1551-1554. doi: 10.3969/j.issn.1006-5725.2011.09.013
|
| [17] |
Chang CH, Qiu J, O'Sullivan D, et al. Metabolic Competition in the Tumor MicroenvironmentIs a Driver of Cancer Progression[J]. Cell, 2015, 162(6): 1229-1241. doi: 10.1016/j.cell.2015.08.016
|
| [18] |
Frauwirth KA, Riley JL, Harris MH, et al. The CD28 signaling pathway regulates glucose metabolism[J]. Immunity, 2002, 16(6): 769-777. doi: 10.1016/S1074-7613(02)00323-0
|
| [19] |
Jacobs SR, Herman CE, Maciver NJ, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways[J]. J Immunol, 2008, 180(7): 4476-4486. doi: 10.4049/jimmunol.180.7.4476
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: